Sustained-Release Interleukin-12 Microspheres in the Treatment of Cancer
- 1 January 1999
- journal article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 25 (9) , 995-1004
- https://doi.org/10.1081/ddc-100102262
Abstract
(1999). Sustained-Release Interleukin-12 Microspheres in the Treatment of Cancer. Drug Development and Industrial Pharmacy: Vol. 25, No. 9, pp. 995-1004. doi: 10.1081/DDC-100102262Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of Microspheres Containing Cytokine Neutralizing Antibodies in EndotoxemiaDrug Development and Industrial Pharmacy, 1999
- Antitumor and antimetastatic effects of interleukin 12Cancer Chemotherapy and Pharmacology, 1996
- Antitumor activity of interleukin 12 in preclinical modelsCancer Chemotherapy and Pharmacology, 1996
- In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphomaClinical & Experimental Metastasis, 1996
- Interleukin-12 an integral cytokine in the immune responseLife Sciences, 1996
- Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.The Journal of Immunology, 1995
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.The Journal of Experimental Medicine, 1993
- Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.The Journal of Experimental Medicine, 1989
- Serum Albumin Beads: An Injectable, Biodegradable System for the Sustained Release of DrugsScience, 1981